Direct angiotensin II type 2 receptor stimulation decreases dopamine synthesis in the rat striatum

Neuropharmacology

Volumn 58, Issue 7, 2010, Pages 1038-1044

  Mertens, Birgit ^a   Vanderheyden, Patrick ^a   Michotte, Yvette ^a   Sarre, Sophie ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

AT2 receptor agonist; Dopaminergic system; In vivo microdialysis; Renin angiotensin system; Striatum; Tyrosine hydroxylase activity

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; 3,4 DIHYDROXYPHENYLACETIC ACID; ANGIOTENSIN 2 RECEPTOR; CANDESARTAN; DOPAMINE; HORMONE RECEPTOR STIMULATING AGENT; N BUTYLOXYCARBONYL 3 (4 IMIDAZOL 1 YLMETHYLPHENYL) 5 ISOBUTYLTHIOPHENE 2 SULFONAMIDE; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BIOSYNTHESIS; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE METABOLISM; DOPAMINE RELEASE; DRUG ACTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TISSUE LEVEL; ENZYME ACTIVITY; GENE ACTIVATION; MALE; MICRODIALYSIS; MODULATION; NONHUMAN; PRIORITY JOURNAL; RAT;

3,4-DIHYDROXYPHENYLACETIC ACID; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BENZIMIDAZOLES; CATHETERIZATION; CENTRAL NERVOUS SYSTEM AGENTS; CORPUS STRIATUM; DOPA DECARBOXYLASE; DOPAMINE; EXTRACELLULAR SPACE; HYDRAZINES; IMIDAZOLES; LEVODOPA; MALE; MICRODIALYSIS; PYRIDINES; RATS; RATS, WISTAR; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; TETRAZOLES; TYROSINE 3-MONOOXYGENASE;

EID: 77950955706     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2010.01.009     Document Type: Article

References (46)

1. AbdAlla S., Lother H., Abdel-tawab A.M., Quitterer U. The angiotensin II AT2 receptor is an AT1 receptor antagonist. J. Biol. Chem. 2001, 276:39721-39726.
2. Bobrovskaya L., Gilligan C., Bolster E.K., Flaherty J.J., Dickson P.W., Dunkley P.R. Sustained phosphorylation of tyrosine hydroxylase at serine 40: a novel mechanism for maintenance of catecholamine synthesis. J. Neurochem. 2007, 100:479-489.
3. Brown D.C., Steward L.J., Ge J., Barnes N.M. Ability of angiotensin II to modulate striatal dopamine release via the AT1 receptor in vitro and in vivo. Br. J. Pharmacol. 1996, 118:414-420.
4. Cervenka L., Wang C.T., Navar L.G. Effects of acute AT1 receptor blockade by candesartan on arterial pressure and renal function in rats. Am. J. Physiol. 1998, 274:F940-F945.
5. Cote F., Do T.H., Laflamme L., Gallo J.M., Gallo-Payet N. Activation of the AT(2) receptor of angiotensin II induces neurite outgrowth and cell migration in microexplant cultures of the cerebellum. J. Biol. Chem. 1999, 274:31686-31692.
6. Culman J., Blume A., Gohlke P., Unger T. The renin-angiotensin system in the brain: possible therapeutic implications for AT(1)-receptor blockers. J. Hum. Hypertens. 2002, 16(Suppl. 3):S64-S70.
7. de Gasparo M., Catt K.J., Inagami T., Wright J.W., Unger T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol. Rev. 2000, 52:415-472.
8. Dwoskin L.P., Jewell A.L., Cassis L.A. DuP 753, a nonpeptide angiotensin II-1 receptor antagonist, alters dopaminergic function in rat striatum. Naunyn Schmiedebergs Arch. Pharmacol. 1992, 345:153-159.
9. Eisenhofer G., Kopin I.J., Goldstein D.S. Catecholamine metabolism: a contemporary view with implications for physiology and medicine. Pharmacol. Rev. 2004, 56:331-349.
10. Elverfors A., Pileblad E., Lagerkvist S., Bergquist F., Jonason J., Nissbrandt H. 3-Methoxytyramine formation following monoamine oxidase inhibition is a poor index of dendritic dopamine release in the substantia nigra. J. Neurochem. 1997, 69:1684-1692.
11. Fernandez B.E., Dominguez A.E. Angiotensin II increases MAO activity in rat central nervous system. Rev. Esp. Fisiol. 1991, 47:37-40.
12. Fischer-Ferraro C., Nahmod V.E., Goldstein D.J., Finkielman S. Angiotensin and renin in rat and dog brain. J. Exp. Med. 1971, 133:353-361.
13. Funke-Kaiser H., Reinemund J., Steckelings U.M., Unger T. Adapter proteins and promoter regulation of the angiotensin II type 2 receptor - implications for cardiac pathophysiology. J. Renin Angiotensin Aldosterone Syst 2009, 10.1177/1470320309343652.
14. Gagnaire F., Chalansonnet M., Carabin N., Micillino J.C. Effects of subchronic exposure to styrene on the extracellular and tissue levels of dopamine, serotonin and their metabolites in rat brain. Arch. Toxicol. 2006, 80:703-712.
15. Gohlke P., Von Kugelgen S., Jurgensen T., Kox T., Rascher W., Culman J., Unger T. Effects of orally applied candesartan cilexetil on central responses to angiotensin II in conscious rats. J. Hypertens. 2002, 20:909-918.
16. Grady E.F., Sechi L.A., Griffin C.A., Schambelan M., Kalinyak J.E. Expression of AT2 receptors in the developing rat fetus. J. Clin. Invest. 1991, 88:921-933.
17. Karamyan V.T., Speth R.C. Distribution of the non-AT1, non-AT2 angiotensin-binding site in the rat brain: preliminary characterization. Neuroendocrinology 2008, 88:256-265.
18. Kaschina E., Grzesiak A., Li J., Foryst-Ludwig A., Timm M., Rompe F., Sommerfeld M., Kemnitz U.R., Curato C., Namsolleck P., Tschope C., Hallberg A., Alterman M., Hucko T., Paetsch I., Dietrich T., Schnackenburg B., Graf K., Dahlof B., Kintscher U., Unger T., Steckelings U.M. Angiotensin II type 2 receptor stimulation: a novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction?. Circulation 2008, 118:2523-2532.
19. Kumer S.C., Vrana K.E. Intricate regulation of tyrosine hydroxylase activity and gene expression. J. Neurochem. 1996, 67:443-462.
20. Laflamme L., Gasparo M., Gallo J.M., Payet M.D., Gallo-Payet N. Angiotensin II induction of neurite outgrowth by AT2 receptors in NG108-15 cells. Effect counteracted by the AT1 receptors. J. Biol. Chem. 1996, 271:22729-22735.
21. Li J., Culman J., Hortnagl H., Zhao Y., Gerova N., Timm M., Blume A., Zimmermann M., Seidel K., Dirnagl U., Unger T. Angiotensin AT2 receptor protects against cerebral ischemia-induced neuronal injury. Faseb J. 2005, 19:617-619.
22. Lopez Verrilli M.A., Pirola C.J., Pascual M.M., Dominici F.P., Turyn D., Gironacci M.M. Angiotensin-(1-7) through AT receptors mediates tyrosine hydroxylase degradation via the ubiquitin-proteasome pathway. J. Neurochem. 2009, 109:326-335.
23. Macova M., Pavel J., Saavedra J.M. A peripherally administered, centrally acting angiotensin II AT2 antagonist selectively increases brain AT1 receptors and decreases brain tyrosine hydroxylase transcription, pituitary vasopressin and ACTH. Brain Res. 2009, 1250:130-140.
24. Meffert S., Stoll M., Steckelings U.M., Bottari S.P., Unger T. The angiotensin II AT2 receptor inhibits proliferation and promotes differentiation in PC12W cells. Mol. Cell. Endocrinol. 1996, 122:59-67.
25. Mendelsohn F.A., Quirion R., Saavedra J.M., Aguilera G., Catt K.J. Autoradiographic localization of angiotensin II receptors in rat brain. Proc. Natl. Acad. Sci. U. S. A. 1984, 81:1575-1579.
26. Mendelsohn F.A., Jenkins T.A., Berkovic S.F. Effects of angiotensin II on dopamine and serotonin turnover in the striatum of conscious rats. Brain Res. 1993, 613:221-229.
27. Mertens, B., Vanderheyden, P., Michotte, Y., Sarre, S., 2009. Role of the central renin angiotensin system in Parkinson's disease. J. Renin Angiotensin Aldosterone Syst. doi:10.1177/147032%200309347789.
28. Paxinos, G. & Watson, C., 1998. The rat brain in stereotaxic coordinates. Academic Press, San Diego.
29. Phillips M.I., de Oliveira E.M. Brain renin angiotensin in disease. J. Mol. Med. 2008, 86:715-722.
30. Sarre S., Michotte Y., Herregodts P., Deleu D., De Klippel N., Ebinger G. High-performance liquid chromatography with electrochemical detection for the determination of levodopa, catecholamines and their metabolites in rat brain dialysates. J. Chromatogr. 1992, 575:207-212.
31. Sarre S., Lanza M., Makovec F., Artusi R., Caselli G., Michotte Y. In vivo neurochemical effects of the NR2B selective NMDA receptor antagonist CR 3394 in 6-hydroxydopamine lesioned rats. Eur. J. Pharmacol. 2008, 584:297-305.
32. Song K., Kanehara H., Takai S., Shiota N., Wada T., Inada Y., Miyazaki M. Inhibition of the angiotensin II type 1 receptor by TCV-116: quantitation by in vitro autoradiography. Jpn. J. Pharmacol. 1999, 79:131-139.
33. Stachowiak M.K., Jiang H.K., Poisner A.M., Tuominen R.K., Hong J.S. Short and long term regulation of catecholamine biosynthetic enzymes by angiotensin in cultured adrenal medullary cells. Molecular mechanisms and nature of second messenger systems. J. Biol. Chem. 1990, 265:4694-4702.
34. Stragier B., Sarre S., Vanderheyden P., Vauquelin G., Fournie-Zaluski M.C., Ebinger G., Michotte Y. Metabolism of angiotensin II is required for its in vivo effect on dopamine release in the striatum of the rat. J. Neurochem. 2004, 90:1251-1257.
35. Stroth U., Meffert S., Gallinat S., Unger T. Angiotensin II and NGF differentially influence microtubule proteins in PC12W cells: role of the AT2 receptor. Brain Res. Mol. Brain Res. 1998, 53:187-195.
36. Sumners C., Shalit S.L., Kalberg C.J., Raizada M.K. Norepinephrine metabolism in neuronal cultures is increased by angiotensin II. Am. J. Physiol. 1987, 252:C650-C656.
37. Szidonya L., Cserzo M., Hunyady L. Dimerization and oligomerization of G-protein-coupled receptors: debated structures with established and emerging functions. J. Endocrinol. 2008, 196:435-453.
38. Takekoshi K., Ishii K., Isobe K., Nanmoku T., Kawakami Y., Nakai T. Angiotensin-II subtype 2 receptor agonist (CGP-42112) inhibits catecholamine biosynthesis in cultured porcine adrenal medullary chromaffin cells. Biochem. Biophys. Res. Commun. 2000, 272:544-550.
39. Takekoshi K., Ishii K., Kawakami Y., Isobe K., Nakai T. Activation of angiotensin II subtype 2 receptor induces catecholamine release in an extracellular Ca(2+)-dependent manner through a decrease of cyclic guanosine 3′,5′-monophosphate production in cultured porcine adrenal medullary chromaffin Cells. Endocrinology 2001, 142:3075-3086.
40. Takekoshi K., Ishii K., Shibuya S., Kawakami Y., Isobe K., Nakai T. Angiotensin II type 2 receptor counter-regulates type 1 receptor in catecholamine synthesis in cultured porcine adrenal medullary chromaffin cells. Hypertension 2002, 39:142-148.
41. Tomaszewicz M., Micossi L.G., Bielarczyk H., Luszawska D., Santarelli I., Szutowicz A. Differential effects of angiotensin II and eledoisin on monoamine oxidase A and B activities in rat brain. J. Neurochem. 1991, 56:729-732.
42. Wan Y., Wallinder C., Plouffe B., Beaudry H., Mahalingam A.K., Wu X., Johansson B., Holm M., Botoros M., Karlen A., Pettersson A., Nyberg F., Fandriks L., Gallo-Payet N., Hallberg A., Alterman M. Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist. J. Med. Chem. 2004, 47:5995-6008.
43. Westerink B.H., De Vries J.B., Duran R. Use of microdialysis for monitoring tyrosine hydroxylase activity in the brain of conscious rats. J. Neurochem. 1990, 54:381-387.
44. Yu K., Lu D., Rowland N.E., Raizada M.K. Angiotensin II regulation of tyrosine hydroxylase gene expression in the neuronal cultures of normotensive and spontaneously hypertensive rats. Endocrinology 1996, 137:3566-3576.
45. Zetterstrom T., Sharp T., Collin A.K., Ungerstedt U. In vivo measurement of extracellular dopamine and DOPAC in rat striatum after various dopamine-releasing drugs; implications for the origin of extracellular DOPAC. Eur. J. Pharmacol. 1988, 148:327-334.
46. Zhou J., Pavel J., Macova M., Yu Z.X., Imboden H., Ge L., Nishioku T., Dou J., Delgiacco E., Saavedra J.M. AT1 receptor blockade regulates the local angiotensin II system in cerebral microvessels from spontaneously hypertensive rats. Stroke 2006, 37:1271-1276.